Jim Cramer discussed Abbott Laboratories (NYSE:ABT) and expressed disappointment over the firm’s recent earnings results and tariff impact. Despite the downturn, Cramer remains optimistic about the company long-term. Investors seeking AI stocks with potential for high returns and minimal risk should explore other options. Find out more in our free report.

Abbott Laboratories (NYSE:ABT) was one of Cramer’s favorite companies before the recent earnings report. The medical device maker often faces misinterpretation during earnings season, leading to temporary stock dips as disappointed sellers emerge. Cramer advises patience and strategic entry points for potential investors.

While ABT remains a viable investment option, other AI stocks may offer better returns with lower risk. Investors interested in AI opportunities should consider exploring alternative options. For more insights on short-term AI stocks and potential hidden gems, check out our recommended reports.

Read more at Yahoo Finance: I Am Very Upset With Abbott,” Says Jim Cramer